What does Research and Medical Distribution do?

Research and Medical Distribution is a road haulage company in Brugge. Private Limited, started on 5 March 2020, 2 establishments.

What is the address of Research and Medical Distribution?

The registered office of Research and Medical Distribution is located at Rederskaai 39 box 501, 8380 Brugge.

Is Research and Medical Distribution still active?

Yes. According to the CBE (31 October 2026) Research and Medical Distribution is active, legal situation “Normale toestand”, started on 5 March 2020.

Is Research and Medical Distribution registered on Peppol?

Yes, Research and Medical Distribution is registered on the Peppol network with ID 0208:0744777876.

What is the enterprise number of Research and Medical Distribution?

The enterprise number of Research and Medical Distribution is BE0744777876.

When was Research and Medical Distribution founded?

Research and Medical Distribution was founded on 5 March 2020.

Is Research and Medical Distribution a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 March 2020; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account; 2 establishments in the CBE.

How much profit did Research and Medical Distribution make in 2025?

Research and Medical Distribution recorded a loss after taxes of € 8,761 in financial year 2025.

What is the revenue of Research and Medical Distribution?

As a small company, Research and Medical Distribution is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 2,098.

Research and Medical Distribution (Private Limited)

Q: Who are the directors of Research and Medical Distribution?

According to the 2025 annual accounts, the directors of Research and Medical Distribution are: Peter Everaerts, Financial Management Bosmans BV, Nobilis Consulting BVBA.

Dossier Research and Medical Distribution, printed on 1 November 2026 from databakkes.be/en/0744777876/research-and-medical-distribution. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Research and Medical Distribution from Brugge, company number BE0744777876, closed financial year 2025 with a result of € -8,761 after tax. For that financial year Research and Medical Distribution recorded a gross margin of € 2,098 and equity of € 64,429. Compared with financial year 2024, the result moved from € 14,543 to € -8,761. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 18, 2026.

What it is worth Healthy

€ 64,429

▼ 12% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -8,761

▼ still € 14,543 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 13,115

▼ 77% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 32,429.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 21,599

▲ € 20,857 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 20,461

▲ € 18,109 vs 2024

€ 12,420 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 19,856

▼ 65% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 46,180 Gross margin 2022: € 46,180 First fiscal year in the series	€ 36,169 Gross margin 2023: € 36,169 ▼ 22% vs 2022 (€ 46,180) Unfavourable step	€ 28,578 Gross margin 2024: € 28,578 ▼ 21% vs 2023 (€ 36,169) Unfavourable step	€ 2,098 Gross margin 2025: € 2,098 ▼ 93% vs 2024 (€ 28,578) Unfavourable step	▼ 93%
Profit after taxes	€ 23,029 Profit after taxes 2022: € 23,029 First fiscal year in the series	€ 19,176 Profit after taxes 2023: € 19,176 ▼ 17% vs 2022 (€ 23,029) Unfavourable step	€ 14,543 Profit after taxes 2024: € 14,543 ▼ 24% vs 2023 (€ 19,176) Unfavourable step	€ -8,761 Profit after taxes 2025: € -8,761 ▼ € 23,304 vs 2024 (€ 14,543) Unfavourable step	▼ € 23,304
Equity	€ 79,471 Equity 2022: € 79,471 First fiscal year in the series	€ 98,647 Equity 2023: € 98,647 ▲ 24% vs 2022 (€ 79,471) Favourable step	€ 73,190 Equity 2024: € 73,190 ▼ 26% vs 2023 (€ 98,647) Unfavourable step	€ 64,429 Equity 2025: € 64,429 ▼ 12% vs 2024 (€ 73,190) Unfavourable step	▼ 12%
Total debts	€ 106,988 Total debts 2022: € 106,988 First fiscal year in the series	€ 60,463 Total debts 2023: € 60,463 ▼ 43% vs 2022 (€ 106,988) Favourable step	€ 58,890 Total debts 2024: € 58,890 ▼ 3% vs 2023 (€ 60,463) Favourable step	€ 40,317 Total debts 2025: € 40,317 ▼ 32% vs 2024 (€ 58,890) Favourable step	▼ 32%
Cash	€ 78,046 Cash 2022: € 78,046 First fiscal year in the series	€ 77,358 Cash 2023: € 77,358 ▼ 1% vs 2022 (€ 78,046) Unfavourable step	€ 56,384 Cash 2024: € 56,384 ▼ 27% vs 2023 (€ 77,358) Unfavourable step	€ 13,115 Cash 2025: € 13,115 ▼ 77% vs 2024 (€ 56,384) Unfavourable step	▼ 77%
Retained profit	€ 47,471 Retained profit 2022: € 47,471 First fiscal year in the series	€ 66,647 Retained profit 2023: € 66,647 ▲ 40% vs 2022 (€ 47,471) Favourable step	€ 41,190 Retained profit 2024: € 41,190 ▼ 38% vs 2023 (€ 66,647) Unfavourable step	€ 32,429 Retained profit 2025: € 32,429 ▼ 21% vs 2024 (€ 41,190) Unfavourable step	▼ 21%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 40,000 Dividend 2024: € 40,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 40,000) Unchanged	▼ 100%
Bank debt	€ 5,593 Bank debt 2022: € 5,593 First fiscal year in the series	€ 3,984 Bank debt 2023: € 3,984 ▼ 29% vs 2022 (€ 5,593) Favourable step	€ 2,352 Bank debt 2024: € 2,352 ▼ 41% vs 2023 (€ 3,984) Favourable step	€ 20,461 Bank debt 2025: € 20,461 ▲ € 18,109 vs 2024 (€ 2,352) Unfavourable step	▲ € 18,109
Balance sheet total	€ 186,459 Balance sheet total 2022: € 186,459 First fiscal year in the series	€ 159,110 Balance sheet total 2023: € 159,110 ▼ 15% vs 2022 (€ 186,459) Unchanged	€ 132,080 Balance sheet total 2024: € 132,080 ▼ 17% vs 2023 (€ 159,110) Unchanged	€ 104,746 Balance sheet total 2025: € 104,746 ▼ 21% vs 2024 (€ 132,080) Unchanged	▼ 21%

Key figures of Research and Medical Distribution, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Research and Medical Distribution?

What happened at Research and Medical Distribution in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 18, 2026 New annual accounts for financial year 2025: loss of € 8,761 (▼ € 23,304 vs 2024). Source: NBB ↗
Jun 1, 2022 New establishment in Aalst. KBO
2022 Financial Management Bosmans BV became a director. NBB
2022 Nobilis Consulting BVBA became a director. NBB
Mar 5, 2020 New establishment in Brugge. KBO
Mar 5, 2020 Start of the company according to the CBE. KBO

In short

From € 23,029 profit in 2022 to € 8,761 loss in 2025.

Paid € 14,003 in corporate taxes since 2022.

Best year ever: 2022, with € 23,029 profit.

Paid out € 40,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Peter Everaerts Financial Management Bosmans BV Nobilis Consulting BVBA

Research and Medical Distribution

MERGAN&PARTNERS

Behind Research and Medical Distribution are Peter Everaerts, Financial Management Bosmans BV and Nobilis Consulting BVBA. Financial Management Bosmans BV is also behind MERGAN&PARTNERS.

Directors

According to the 2025 annual accounts

Peter Everaerts

Director

Financial Management Bosmans BV

Managing director · represented by Jellen Bosmans

Also active at: MERGAN&PARTNERS

since 2022

Nobilis Consulting BVBA

Director · represented by Jelle Willems

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Rederskaai 39 box 501

8380 Brugge

2.336.554.113

Fonteinbos 23

9320 Aalst

Active since 1 June 2022

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

POMI INVESTMENTS

€ 11,261 gross margin · 2023

ShipCo

€ 244,361 gross margin · 2025

Vereniging van Mede-eigenaars Residentie Le Dauphin Brugge(Zeebrugge) Rederskaai 39-41

DANYO TRANSPORT

€ 303,615 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0744.777.876
VAT number: BE 0744.777.876
Registered office: Rederskaai 39 bus 501, 8380 Brugge
Names & denominations: Research and Medical Distribution · ReMeDi
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 5 March 2020
Peppol: Active · Active since 27 Mar 2026
Activities · NACE: Goederenvervoer over de weg

View on CBE Public ↗ Annual accounts (NBB) ↗